Over the next decade, nanotechnology has the potential to influence virtually every aspect of our lives, including our energy, food, water, buildings, and medicines. According to a recently published report by BCC Research, the market value of the worldwide nanomedicine industry alone is estimated to grow at a CAGR of 12.5% to reach $130.9 billion by the fiscal year 2016. However, in order to realize this broad potential - robust, cost-effective, regulatory-friendly manufacturing technologies will be required. Through its novel technology platform and expansive intellectual property, Liquidia is poised to be a leader in the development of nanotechnology-based healthcare products and a catalyst for the growth anticipated across this industry.
Liquidia has established a powerful and versatile nanotechnology-based product development platform that is revolutionizing the way that companies engineer healthcare products. By leveraging fabrication techniques from the semiconductor industry, Liquidia has the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape, or composition. This unique ability to precisely engineer particles enables scientists to explore new product frontiers that, until now, have otherwise been out of reach. Using the company’s proprietary PRINT Platform, Liquidia is creating precisely engineered vaccines, therapeutics and other health-related products.
Liquidia was founded based on technology licensed from the DeSimone research group at the University of North Carolina – Chapel Hill (UNC). Dr. DeSimone is a prolific scientist and entrepreneur the recipient of numerous awards and recognitions including the prestigious Lemelson-MIT Prize for inventors, the 2009 NIH Director's Pioneer Award and is credited with over 100 issued patents and nearly 300 published articles. Dr. DeSimone currently serves as a senior scientific advisor to Liquidia.
To learn more about the PRINT technology, click here.